We examined the activities of peptidases in plasma and tissues of the New Zealand Black (NZB) mouse as an animal model of human systemic lupus erythematosus, and also in serum from patients with rheumatoid arthritis and systemic lupus erythematosus. Activities of dipeptidyl peptidase Ii (DAP II) and post-proline cleaving enzyme (PPCE) were increased, and dipeptidyl peptidase IV (DAP IV) activity was decreased in plasma and spleen of NZB mice, as compared with the control BALB/c mice. Likewise, the activity of DAP II was increased and that of DAP IV was decreased in serum of patients with rheumatoid arthritis and systemic lupus erythematosus. These results indicate the importance of hydrolytic enzymes in the pathogenesis of autoimmune diseases.
autoimmune disease
Dipeptidyl peptidase II (EC 3.4.14.2; DAP II) and dipeptidyl peptidase N (EC 3.4.14.5; DAP N), both dipeptidylpeptide hydrolases, cleave dipeptide from unsubstituted NH2 termini of dipeptide derivatives.1 DAP II differs from DAP N in its substrate specificity, subcellular localization, and pH optimum. DAP II, a serine peptidase with a restricted substrate specificity, hydrolyzes preferentially Lys-Ala-2-naphthylamide at pH 5.5, but also cleaves the N-terminal dipeptide from dipeptide 2-naphthylamides and tripeptides with a penultimate alanyl or prolyl residue (1). DAP N, also a serine peptidase, hydrolyzes peptides having an N-terminal sequenceof X-Pro-Y-to yield X-Pro and Y-at pH 8.0(2).
Using a new and specific assay for DAP II activity with 7-Lys-Ala-4-methylcoumarinamide (Lys-Ala-MCA) as a fluorogenic substrate, we recently found that DAP II activity was increased in serum from cancer patients, whereas DAP N activity was decreased (3,4). We also found that serum DAP II activity was increased in tumor-bearing mice having increased ratios of DAP il/DAP N activities (4) .
In a recent study, Aoyagi et al. We have examined DAP II and DAP IV activities, and their ratios, in plasma and tissues of NZB mice with lupus erythematosus-like syndrome and in human serum from patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). We also examined the activities of PPCE and collagenase-like peptidase (CL-peptidase) in plasma and tissues of NZB mice, and compared these with the DAP II and DAP N activities.
Materials and Methods
Samples. NZB mice and BALB/c mice were obtained from Charles River Laboratories, Japan Inc., Atsugi, Kanagawa 243-02, Japan. BALB/c mice were used as controls. We used only female mice in these experiments, killing them by decapitation at three, six, 12, 15, 20, or 25 weeks of age. We also assayed serum samples from patients with RA or SLE. Mouse tissues and human sera were stored at -80 #{176}C until assay. We homogenized the mouse tissues in 0.25 mol/L sucrose solution, centrifuged the homogenate at 30 000 x g for 20 mm, and measured enzymatic activities in the supernate. Enzyme activity. All enzyme activities were assayed fluorometrically by measuring the enzymatic formation of 7-amino-4-methylcoumarin.
DAP II activity was measured by "high-performance" liquid chromatography with fluorometnc detection, with Lys-Ala-MCA as substrate (2). DAP IV activity was measured fluorometrically, with Gly-Pro-MCA as substrate, as described previously (6). PPCE activity was determined by fluorometry, with (succinyl-Gly-Pro)-MCA as substrate (7) . CL-peptidase activity, with (succmnyl-Gly-ProLeu-Gly-Pro)-MCA as substrate, was assayed by fluorometry of the 7-amino-4-methylcoumarin liberated from the reaction product Gly-Pro-MCA by the second enzyme reaction with DAP N (8) . Protein was assayed by the method of Lowry et al. (9) . IgG, IgA, and complement components C3 and C4 were determined by single radial immunodiffusion (10, 11 Mean ± SD (n = 5) bSignificantlydifferent from controls at: (#{149}) p <0.05; () P <0.02; P <0.01 ; " P <0.005; P <0.001. Table 1 compares the plasma enzyme activities of NZB mice and the control mice. At three weeks of age, the NZB mice had activities of DAP II, DAP IV, PPCE, and CLpeptidase that were significantly lower than those of the controls. Activities ofthree ofthe enzymes stayed below that of the controls, but between 15 and 20 weeks of age the activity of DAP II activity began to increase, leading to a significantly increased ratio DAP Il/DAP N in NZB mice (P <0.005). By 25 weeks of age, the significance of the increased DAP 11/DAP N ratio was P <0.001. Table 2 similarly compares the changes in various enzyme activities in the spleen and kidney of NZB and control mice.
The activities of DAP II and DAP IV in human serum from control patients, patients with RA, and patients with SLE are shown in Table 3 . Data on IgG, IgA, CHse, C3, and C4 are also included. DAP H activity significantly exceeded control values in patients with BA (P <0.01) and in patients with SLE (P <0.001), whereas DAP IV activity was significantly lower in patients with HA (P <0.01) and in patients with SLE (P <0.001). Therefore, the DAP il/DAP IV ratio was also significantly increased in patients with HA (P <0.01) and in patients with SLE (P <0.001).
Discussion
Some studies indicate that hydrolytic enzymes participate in the pathogenesis of immunoallergic disturbances (12-14) , but the specific roles of these enzymes have not yet been elucidated. Table 1 .
To our knowledge, this is the first report of DAP II activity in mice with SLE-like syndrome and in patients with RA or SLE. An interesting finding was the opposite changes in the activities of DAP II and DAP N, which is similar to our previous findings concerning tumor-bearing animals and cancer patients (4).
We found in the present study that plasma DAP H activity increased with age in NZB mice, whereas plasma DAP N activity decreased. Plasma PPCE and CL-peptidase activities were lower in NZB mice than in the control mice.
During maturational development,
DAP II activity in the spleens of NZB mice increased and DAP IV activity decreased; PPCE activity increased gradually with age and became significantly high at 25 weeks of age. The increase in PPCE activity in the spleen with age agrees with the previous report by Aoyagi et al. (5) . Kidney The results in NZB mice prompted us to examine activities of DAP II and DAP N-and the ratios of these two activities-in the serum of patients with RA or SLE. The results tended to agree with the changes seen in NZB mice: DAP U activity in senun was increased and DAP IV activity in serum was decreased, confirming our previous report (15) , and the ratio of DAP II/DAP IV activities in serum was significantly increased. The increase in this ratio was more pronounced in patients with SLE than in patients with RA.
The mechanism and the clinical significance of the increase in this ratio in patients with RA or SLE remain to be further examined. Perhaps the ratio can be developed to be a biochemical index of some autoiminune disease.
